AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1066224
Drug: Local anesthetics
RxNorm normalized name: LOCAL ANESTHETICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetics (3.6 ml submucous injection)
Trial: 30664012
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.2% levobupivacaine (5 ml/h)
Trial: 30664012
Drug: Programmed intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed intermittent bolus infusion of 0.2% levobupivacaine (15 ml every 3h)
Trial: 30664012
Drug: Programmed intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed intermittent bolus infusion of 0.2% levobupivacaine
Trial: 30664012
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.2% levobupivacaine
Trial: 25932549
Drug: Intravitreal bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal bevacizumab 0.16 mg/0.05 mL
Trial: 23798671
Drug: Rifaximin 25
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifaximin 25 mg once daily for 5 days
Trial: 17023279
Drug: Preoperative multiple-injection
RxNorm normalized name: sodium acetate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative multiple-injection thoracic paravertebral blocks (PVB group, n = 25)
Trial: 17023279
Drug: Preoperative multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative multiple subcutaneous saline injections (Control group, n = 25)
Trial: 9337499
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment (voucher incentive program and community reinforcement approach)
Trial: 9337499
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (lifestyle counseling)
Trial: 3527305
Drug: Aminoglutethimide (AG)
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (AG) 1.000 mg/day with hydrocortisone (HC) 20‐40 mg/day
Trial: 24906582
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual plus yoga
Trial: 21833588
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of 75 mg/m² cisplatin plus 75 mg/m² docetaxel, followed by three cycles of 1,200 mg/m² gemcitabine (arm A)
Trial: 21833588
Drug: Three cycles
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three cycles of 25 mg/m² cisplatin plus 25 mg/m² docetaxel, followed by three cycles of 1,200 mg/m² gemcitabine (arm B)
Trial: 17466852
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin 4 times daily for 3 days preoperatively and 1 month postoperatively
Trial: 17466852
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin 4 times daily for 1 month postoperatively
Trial: 17466852
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving only topical steroids and antibiotics
Trial: 17466852
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin preoperatively
Trial: 17466852
Drug: Topical indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical indomethacin postoperatively
Trial: 16326294
Drug: Topical valdecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical valdecoxib
Trial: 12176795
Drug: RPR 109881A
RxNorm normalized name: Nxl-103 component rpr-202868
DrugBank: Linopristin (DB19296)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPR 109881A (1-hour infusion)
Trial: 12176795
Drug: RPR 109881A
RxNorm normalized name: Nxl-103 component rpr-202868
DrugBank: Linopristin (DB19296)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RPR 109881A (3-hour infusion)
Trial: 9447850
Drug: Atenolol (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (0, 5, or 10 mg intravenously before induction of anesthesia and every 12 h after operation until the patient could take oral medications; 0, 50, or 100 mg orally once a day as specified by blood pressure and heart rate)
Trial: 776538
Drug: Lysometra (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lysometra (2.5 ml intramuscular injections for three 20-day courses)
Trial: 776538
Drug: Methylandrostendiol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylandrostendiol (5 mg intramuscular injections for three 20-day courses)
Trial: 31050109
Drug: iGlarLixi 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iGlarLixi 5 U/5 μg
Trial: 31050109
Drug: iGlarLixi 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iGlarLixi 10 U/10 μg
Trial: 31050109
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 5 U
Trial: 25408222
Drug: Macushield (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Macushield (10 mg meso‐zeaxanthin, 10 mg lutein, 2 mg zeaxanthin)
Trial: 23338109
Drug: Lidocaine 3
RxNorm normalized name: Lidocaine 3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine 3 mg/kg with Nitroglycerin 200 µg
Trial: 16446342
Drug: Vinorelbine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine and cisplatin alone (placebo patch, arm B)
Trial: 9466165
Drug: RS-8359 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS-8359 (multiple doses)
Trial: 9466165
Drug: RS-8359 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RS-8359 (single dose)
Trial: 8187308
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg lanreotide (SR-L)
Trial: 8187308
Drug: Long-term treatment
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term treatment with SR-L (2-3 injections/month for 3-6 months)
Trial: 2856773
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) 25 mg once daily
Trial: 3034318
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg + HCTZ 25 mg once daily
Trial: 3034318
Drug: HCTZ 25
RxNorm normalized name: HCTZ 25 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCTZ 25 mg + Captopril 50 mg once daily
Trial: 19819530
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg and standard analgesia (tylenol with codeine)
Trial: 15947595
Drug: Screening arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Screening arm (Prostate specific antigen testing, digital rectal examination, transrectal ultrasound, sextant biopsies)
Trial: 14638545
Drug: Renal insufficiency
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal insufficiency (CrCl ≤60 mL/min)
Trial: 11409184
Drug: Oral doxofylline
RxNorm normalized name: doxofylline
DrugBank: Doxofylline (DB09273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxofylline (400 mg BID)
Trial: 1899136
Drug: Levonorgestrel IUD
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levonorgestrel IUD (20 micrograms daily)
Trial: 26330052
Drug: High-potency topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-potency topical agents
Trial: 26330052
Drug: Regional differences
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regional differences in topical use
Trial: 22192731
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus erlotinib (gemcitabine 1000 mg/m² on day 1, oxaliplatin 100 mg/m² on day 2, erlotinib 100 mg daily)
Trial: 22192731
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (gemcitabine 1000 mg/m² on day 1, oxaliplatin 100 mg/m² on day 2)
Trial: 22192731
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus erlotinib (for cholangiocarcinoma subgroup)
Trial: 22192731
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (for cholangiocarcinoma subgroup)
Trial: 16358997
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose rofecoxib combined with simvastatin
Trial: 16310019
Drug: BWLP+SC [PST]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BWLP+SC [PST] (behavioral weight loss program with stepped-care approach including problem-solving therapy)
Trial: 1992599
Drug: Nilutamide (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilutamide (300 mg/day) plus buserelin
Trial: 6357890
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg intramuscular diclofenac sodium (Voltaren)
Trial: 30203750
Drug: Celecoxib therapy
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib therapy
Trial: 30203750
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium therapy
Trial: 25246338
Drug: Co-infusion of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-infusion of donor adipose-derived mesenchymal stem cells (AD-MSC) + hematopoietic stem cells (HSC)
Trial: 25246338
Drug: No stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No stem cell therapy (Control group)
Trial: 20102716
Drug: Pentoxifylline (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (400 mg, orally, 3 times daily)
Trial: 11966970
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy (active and passive jaw movement exercises, correction of body posture, relaxation techniques)
Trial: 11966970
Drug: Waiting-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list control (no treatment)
Trial: 7594322
Drug: Lansoprazole plus
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole plus low-dose amoxicillin
Trial: 7594322
Drug: Lansoprazole monotherapy
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole monotherapy
Trial: 31743412
Drug: Arrowhead Business
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arrowhead Business Group (ABG) entrepreneurship education intervention; details on dosage and duration not available.
Trial: 15511696
Drug: Zonisamide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide (400 mg QD)
Trial: 8036045
Drug: Erythromycin lactobionate
RxNorm normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin lactobionate 40 mg/kg/day
Trial: 8036045
Drug: Erythromycin lactobionate
RxNorm normalized name: Erythromycin Lactobionate
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erythromycin lactobionate 25 mg/kg/day
Trial: 2838288
Drug: Radiotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy with chemotherapy (RT-CT)
Trial: 25766448
Drug: Cumin cyminum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumin cyminum L. capsule (n = 26)
Trial: 25766448
Drug: Orlistat120 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orlistat120 capsule (n = 26)
Trial: 18474492
Drug: ENF 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENF 180 mg qd
Trial: 18474492
Drug: ENF 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ENF 90 mg bid
Trial: 16401645
Drug: 200mg G115/0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg G115/0 mg glucose (ginseng)
Trial: 16401645
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg G115/25 g glucose (glucose)
Trial: 16401645
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg G115/25 g glucose (ginseng/glucose combination)
Trial: 16401645
Drug: 0mg G115/0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0mg G115/0 mg glucose (placebo)
Trial: 12853380
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of slow-release clarithromycin
Trial: 27121185
Drug: Basic body
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic body awareness treatment
Trial: 25014001
Drug: Escitalopram (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10‐20 mg/d)
Trial: 18853315
Drug: Chloramphenicol 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol 0.2% with polymyxin B 2500 U/ml
Trial: 15339466
Drug: Fufang Sishen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fufang Sishen Decoction (FFSSD), 6 g, b.i.d.
Trial: 15339466
Drug: Propafenone, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone, 150 mg, q 8 h
Trial: 9647301
Drug: Raised antiviral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Raised antiviral antibody titres
Trial: 2678834
Drug: DDP in
RxNorm normalized name: DDP-200
DrugBank: DDP-200 (DB05919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DDP in combination with adriamycin (ADM) and cyclophosphamide
Trial: 26860808
Drug: Flaxseed (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (25 g daily)
Trial: 26860808
Drug: Vitex agnus
RxNorm normalized name: VITEX AGNUS-CASTUS LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitex agnus (3.2‐4.8 mg daily)
Trial: 24225451
Drug: MNP+Zn (Micronutrient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MNP+Zn (Micronutrient Powder with 10 mg of zinc)
Trial: 22431798
Drug: WC2031 (doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WC2031 (doxycycline hyclate delayed-release 200-mg tablet) orally once daily for 7 days
Trial: 22431798
Drug: Vibramycin (doxycycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vibramycin (doxycycline hyclate capsule) 100 mg orally twice daily for 7 days
Trial: 18705027
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium extended-release 250 mg once daily
Trial: 18705027
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium extended-release 500 mg once daily
Trial: 18705027
Drug: Divalproex sodium
RxNorm normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Divalproex sodium extended-release 1000 mg once daily
Trial: 8971298
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg body weight of midazolam
Trial: 1611111
Drug: 100 MU
RxNorm normalized name: Tu Mu Xiang
DrugBank: Inula helenium root (DB14350)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 MU recombinant interferon-alpha 2b intravesically once weekly for 12 weeks and then monthly for up to 1 year
Trial: 1611111
Drug: 10 MU
RxNorm normalized name: saliva substitute comb no.10 MUCOUS MEM POWDER IN PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 MU recombinant interferon-alpha 2b intravesically once weekly for 12 weeks and then monthly for up to 1 year
Trial: 1611111
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (10 MU)
Trial: 1611111
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (100 MU)
Trial: 6704008
Drug: Topical 0.25%
RxNorm normalized name: permethrin topical 0.25% topical kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.25% betaxolol
Trial: 31653510
Drug: Vaccine-KLH conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaccine-KLH conjugate + OPT-821
Trial: 25108545
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate 50 mcg
Trial: 16234333
Drug: 0.5 h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 h infusion of 0.5 g every 6 h
Trial: 16234333
Drug: 2 h
RxNorm normalized name: Type 2 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 h infusion of 0.5 g every 6 h
Trial: 16234333
Drug: 2 h
RxNorm normalized name: Type 2 H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 h infusion of 1 g every 6 h
Trial: 11834876
Drug: L-NMMA (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-NMMA (3 mg/kg over 10 min)
Trial: 11834876
Drug: Norepinephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion (0.1 microg/kg/min over 60 min)
Trial: 3605131
Drug: Extra snack
RxNorm normalized name: Panadol Extra
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra snack at bedtime if capillary blood glucose levels at 10:30 P.M. were 120 mg/dl or less
Trial: 20572368
Drug: Transdermal 17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal 17 beta‐estradiol (50 mg/day) and medroxy progesterone acetate (2.5 mg/day) for 3 months
Trial: 20572368
Drug: Placebo (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (both transdermal and oral)
Trial: 18323719
Drug: Nutrition education
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition education program (5 monthly sessions)
Trial: 11290878
Drug: Vigabatrin (VGB)
DrugBank: Vigabatrin (DB01080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vigabatrin (VGB) 2,000 mg
Trial: 30136291
Drug: Oral taurine
RxNorm normalized name: Taurine
DrugBank: Taurine (DB01956)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral taurine supplementation (2 g/day)
Trial: 27428211
Drug: Vaginal rings
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal rings containing 25 mg dapivirine (DPV)/100 mg maraviroc (MVC)
Trial: 25456370
Drug: Everolimus (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (4.5 mg/m² per day, adjusted for tolerability to attain blood trough concentrations of 5-15 ng/mL)
Trial: 22592573
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg ondansetron in saline
Trial: 22592573
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tramadol in saline
Trial: 9436865
Drug: Combination (Ethanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination (Ethanol + Nifedipine)
Trial: 1204278
Drug: Nabilone 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone 2.5 mg
Trial: 1204278
Drug: Nabilone 5
RxNorm normalized name: nabilone 500 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone 5 mg
Trial: 1204278
Drug: Nabilone 1
RxNorm normalized name: nabilone 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone 1 mg or 2 mg two times daily
Trial: 1204278
Drug: Nabilone 5
RxNorm normalized name: nabilone 500 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone 5 mg after 7-day drug period
Trial: 31948903
Drug: Durvalumab 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1500 mg plus placebo every 4 weeks for 4 cycles, followed by durvalumab 1500 mg every 4 weeks
Trial: 31948903
Drug: Durvalumab 1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks for 4 cycles, followed by durvalumab 1500 mg every 4 weeks
Trial: 31058448
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid injection (100 mL/5 mg) after operation, along with oral calcium carbonate (600 mg/d) and active vitamin D3 (400 IU/d)
Trial: 31058448
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate (600 mg/d) and active vitamin D3 (400 IU/d)
Trial: 21584942
Drug: tofacitinib 1
RxNorm normalized name: tofacitinib 11 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib 1 mg twice a day
Trial: 21584942
Drug: tofacitinib 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib 3 mg twice a day
Trial: 21584942
Drug: tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib 5 mg twice a day
Trial: 21584942
Drug: tofacitinib 10
RxNorm normalized name: tofacitinib 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tofacitinib 10 mg twice a day